Mid-Day Market Update: Gold Rises 1%; Forte Biosciences Shares Plunge
Midway through trading Friday, the Dow traded down 0.23% to 35,361.40 while the NASDAQ rose 0.02% to 15,333.95. The S&P also fell, dropping 0.22% to 4,527.17.
Brookline Capital Downgrades Forte Biosciences to Hold
Brookline Capital analyst Kumaraguru Raja downgrades Forte Biosciences (NASDAQ:FBRX) from Buy to Hold.
Mid-Morning Market Update: Markets Mostly Lower; US Economy Adds 235,000 Jobs In August
Following the market opening Friday, the Dow traded down 0.41% to 35,300.08 while the NASDAQ rose 0.02% to 15,334.73. The S&P also fell, dropping 0.25% to 4,525.66.
Chardan Capital Downgrades Forte Biosciences to Sell, Announces $4 Price Target
Chardan Capital analyst Keay Nakae downgrades Forte Biosciences (NASDAQ:FBRX) from Buy to Sell and announces $4 price target.
Ladenburg Thalmann Downgrades Forte Biosciences to Neutral
Ladenburg Thalmann analyst Michael Higgins downgrades Forte Biosciences (NASDAQ:FBRX) from Buy to Neutral.
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
A Peek Into The Markets: US Stock Futures Rise; All Eyes On Jobs Report
Pre-open movers
U.S. stock futures traded higher in early pre-market trade ahead of the release of jobs report for August. Analysts expect nonfarm payrolls rising 740,000 for August following monthly gains of 943,000 in July. The unemployment rate is projected to drop to 5.2% from 5.4%.
B. Riley Securities Downgrades Forte Biosciences to Neutral, Announces $3 Price Target
B. Riley Securities analyst Kalpit Patel downgrades Forte Biosciences (NASDAQ:FBRX) from Buy to Neutral and announces $3 price target.